Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2025 Earnings Call Transcript
Operator: Greetings, and welcome to the Catalyst Pharmaceuticals Third Quarter 2025 Financial Results Conference Call and webcast. [Operator Instructions].
Catalyst Pharmaceuticals Inc. (CPRX)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deerfield Management James E. Flynn | 4,974,767 | $98,002,910 | +73% | 1.5% |
| 2. | Renaissance Technologies Jim Simons | 3,544,830 | $69,833,151 | +10% | 0.09% |
| 3. | Fundsmith LLP Terry Smith | 3,363,807 | $66,266,998 | +25% | 0.33% |
| 4. | Royce & Associates Chuck Royce | 2,034,965 | $40,088,810 | +29% | 0.4% |
| 5. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 1,304,774 | $25,704,048 | +7% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.99 | 7,000 | $20,930.00 | 560,376 | 2020-09-30 | Filing | |
| $2.97 | 15,000 | $44,550.00 | 4,787,693 | 2020-09-30 | Filing | |
| $4.70 | 10,000 | $46,950.00 | 553,376 | 2019-10-11 | Filing | |
| $4.89 | 10,000 | $48,900.00 | 4,772,693 | 2019-10-03 | Filing | |
| $3.23 | 25,000 | $80,750.00 | 4,762,693 | 2019-06-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $23.33 | 10,983 | $256,244.37 | 3,962 | 2025-11-26 | Filing | |
| $22.70 | 40,000 | $908,000.00 | 231,039 | 2025-11-12 | Filing | |
| $20.30 | 30,000 | $609,000.00 | 271,039 | 2025-09-08 | Filing | |
| $19.52 | 30,000 | $585,600.00 | 188,564 | 2025-09-04 | Filing | |
| $20.08 | 20,000 | $401,600.00 | 188,564 | 2025-09-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 18,216,060 | $358,856,382 | 0.01% | |
| 2. | 8,713,520 | $171,656,344 | 0% | |
| 3. | 6,405,387 | $126,186,124 | 0% | |
| 4. | 2,890,320 | $56,946,376 | 0% | |
| 5. | 2,528,186 | $49,805,264 | 0.03% |
News See All
What do Analysts Think About Catalyst Pharmaceuticals (CPRX)?
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is one of the best biotech stocks with high potential. HC Wainwright reiterated a Buy rating on Catalyst Pharmaceuticals, Inc.
14 Biotech Stocks with High Potential
Healthcare was the second worst performer this year, with pharma and biotech companies under pressure.
Catalyst Pharmaceuticals, Inc. (CPRX) Secures FIRDAPSE Market Exclusivity Until 2035
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a commercial-stage biopharmaceutical company specializing in treatments for rare and difficult-to-treat diseases.
11 Cheap Biotech Stocks to Buy According to Hedge Funds
Mizuho's Jared Holz appeared on CNBC's "Closing Bell Overtime" on July 8 to talk about whether the biotech industry is prepared for a breakthrough.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q2 2025 Earnings Call Transcript
Operator: Greetings, and welcome to the Catalyst Pharmaceuticals Second Quarter 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2025 Earnings Call Transcript
Operator: Good day everyone, and welcome to the Catalyst Pharmaceuticals First Quarter 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
11 Stocks with Consistent Growth to Buy Now
Investors are consistently drawn toward companies that have demonstrated a solid long-term expansion in revenue and earnings.
11 Best Russell 2000 Stocks to Buy According to Wall Street Analysts
Since President Trump announced new tariffs, the U.S. stock market has been steadily declining. The Wall Street Journal has estimated the loss to be around $6.6 trillion.
What Makes Catalyst Pharmaceuticals (CPRX) an Investment Choice?
Renaissance Investment Management, an investment management company, released its Q4 2024 “Small Cap Growth Strategy” investor letter. A copy of the letter can be downloaded here.